Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$0.51 USD
-0.02 (-3.13%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $0.50 -0.01 (-2.15%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Atara Biotherapeutics, Inc. [ATRA]
Reports for Purchase
Showing records 101 - 108 ( 108 total )
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We like the Initial ATA188 Data in Progressive MS. Dose Response Is Key.
Provider: Roth Capital Partners, Inc.
Analyst: CALCAGNINI THOMAS
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provides Update For FDA Filing - Reiterate Buy Rating and $30 PT
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cell Therapy 2.0: Moving Beyond CAR-Ts in Immuno-Oncology
Provider: Roth Capital Partners, Inc.
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are initiating coverage on Atara Biotherapeutics with a Buy rating and $30 PT
Provider: Roth Capital Partners, Inc.